Select ongoing or completed combination studies in untreated FL
| Regimen . | Phase . | N . | ORR (CR) . | PFS . | Ref. . |
|---|---|---|---|---|---|
| Lenalidomide + rituximab | 2 | 50 | 98% (87%) | 75% (3 y) | 26 |
| Lenalidomide + rituximab | 2 | 65 | 96% (71%) | 89% (2 y) | 27 |
| Lenalidomide + rituximab* | 2 | 77 | 81% (36%) | NR | 44 |
| Lenalidomide + rituximab vs R-Chemo | 3 | 1000 | TBD | TBD | Clinicaltrials.gov |
| Ibrutinib + rituximab | 2 | 60 | 80% (27%) | 86% (12 mo) | 33 |
| Ibrutinib + rituximab + lenalidomide | 1 | 22 | 91% (63%) | 84% (12 mo) | 34 |
| Idelalisib + rituximab* | 2 | — | NR | NR | Terminated |
| Sargramostim + rituximab | 2 | 52 | 74% (42%) | 54% (2 y) | 45 |
| Galiximab + rituximab | 2 | 61 | 72% (48%) | 58% (2 y) | 32 |
| Regimen . | Phase . | N . | ORR (CR) . | PFS . | Ref. . |
|---|---|---|---|---|---|
| Lenalidomide + rituximab | 2 | 50 | 98% (87%) | 75% (3 y) | 26 |
| Lenalidomide + rituximab | 2 | 65 | 96% (71%) | 89% (2 y) | 27 |
| Lenalidomide + rituximab* | 2 | 77 | 81% (36%) | NR | 44 |
| Lenalidomide + rituximab vs R-Chemo | 3 | 1000 | TBD | TBD | Clinicaltrials.gov |
| Ibrutinib + rituximab | 2 | 60 | 80% (27%) | 86% (12 mo) | 33 |
| Ibrutinib + rituximab + lenalidomide | 1 | 22 | 91% (63%) | 84% (12 mo) | 34 |
| Idelalisib + rituximab* | 2 | — | NR | NR | Terminated |
| Sargramostim + rituximab | 2 | 52 | 74% (42%) | 54% (2 y) | 45 |
| Galiximab + rituximab | 2 | 61 | 72% (48%) | 58% (2 y) | 32 |
Single-arm results from randomized study.